Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Oncology Endpoint Guidance: US FDA Reaffirms Support For EFS, MRD In Update

Dec 20 2018

• By Michael Cipriano

Cancer cells

Related Content

Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication

Sep 04 2017

Pfizer Hopes To Convince FDA With Event-Free Survival Data For Mylotarg

Jul 10 2017

Mylotarg, Event-Free Survival Endpoint Both Get FDA Panel Endorsement

Jul 11 2017

FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint

Mar 30 2018

Amgen's Blincyto Has 'Potential Benefit' For MRD ALL, But Approval Chances Remain Unclear

Mar 07 2018

Guidance By Guidance, US FDA Is Reshaping The Look Of Cancer Drug Trials

Aug 30 2018

US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products

Jul 26 2018

Keeping Track: Pfizer’s Talzenna Ensures Record Year For Novel US Approvals; Novartis Submits SMA Gene Therapy

Oct 22 2018

Metastasis-Free Survival Endpoint Spreads To Labeling With US FDA Approval Of J&J's Erleada

Feb 14 2018

Related Companies

Pfizer Inc.

Novartis AG

Amgen, Inc.

Johnson & Johnson

Additional Topics

United States Clinical Trials Drug Approval Standards Regulation Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window